Statin therapy did not improve the in-hospital outcome of coronavirus disease 2019 (COVID-19) infection.
Diabetes Metab Syndr
; 14(6): 1613-1615, 2020.
Article
in English
| MEDLINE | ID: covidwho-1059529
ABSTRACT
BACKGROUND AND AIMS:
The coronavirus disease 2019 (COVID-19) number of death cases is still increasing. One of the comorbidities associated with severe outcome and mortality of COVID-19 is dyslipidemia. Statin is one of the drugs which is most commonly used for the treatment of dyslipidemic patients. This study aims to analyze the association between statin use and in-hospital outcomes of COVID-19 infection.METHODS:
We systematically searched the Google Scholar database using specific keywords related to our aims until August 1st, 2020. All articles published on COVID-19 and statin were retrieved. Statistical analysis was done using Review Manager 5.4 software.RESULTS:
A total of 9 studies with a total of 3449 patients were included in our analysis. Our meta-analysis showed that statin use did not improve severity outcome [OR 1.64 (95% CI 0.51-5.23), p = 0.41, I2 = 93%, random-effect modelling] nor mortality rate from COVID-19 infection [OR 0.78 (95% CI 0.50-1.21), p = 0.26, I2 = 0%, fixed-effect modelling].CONCLUSION:
Statin use did not improve in-hospital outcomes of COVID-19 infections. Patients with dyslipidemia should continue taking statin drugs despite COVID-19 infection status, given its beneficial effects on cardiovascular outcomes.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/
Dyslipidemias
/
COVID-19
/
COVID-19 Drug Treatment
/
Hospitalization
Type of study:
Observational study
/
Prognostic study
/
Randomized controlled trials
/
Reviews
Limits:
Humans
Language:
English
Journal:
Diabetes Metab Syndr
Year:
2020
Document Type:
Article
Affiliation country:
J.dsx.2020.08.023
Similar
MEDLINE
...
LILACS
LIS